scholarly journals The prognostic effect of adjuvant chemotherapy in the colon cancer patients with solitary lymph node metastasis

2019 ◽  
Vol 34 (8) ◽  
pp. 1483-1490
Author(s):  
Seung-Seop Yeom ◽  
Soo Young Lee ◽  
Chang Hyun Kim ◽  
Hyeong Rok Kim ◽  
Young Jin Kim
2020 ◽  
Author(s):  
Xiangjian Zheng ◽  
Xiaodong Chen ◽  
Min Li ◽  
Chunmeng Li ◽  
Xian Shen

Abstract Background: Surgery combined with chemo-radiotherapy is a recognized model for the treatment of gastric and colon cancers. Lymph node metastasis determines the patient's surgical or comprehensive treatment plan. This analytical study aims to compare preoperative prediction scores to better predict lymph node metastasis in gastric and colon cancer patients.Methods: This study comprised 768 patients, which included 312 patients with gastric cancer and 462 with colon cancer. Preoperative clinical tumor characteristics, serum markers, and immune indices were evaluated using single-factor analysis. Logistic analysis was designed to recognize independent predictors of lymph node metastasis in these patients. The independent risk factors were integrated into preoperative prediction scores, which were accurately assessed using receiver operating characteristic (ROC) curves.Results: Results showed that serum markers (CA125, hemoglobin, albumin), immune indices (S100, CD31, d2–40), and tumor characteristics (pathological type, size) were independent risk factors for lymph node metastasis in patients with gastric and colon cancer. The preoperative prediction scores reliably predicted lymph node metastasis in gastric and colon cancer patients with a higher area under the ROC curve (0.901). The area was 0.923 and 0.870 in gastric cancer and colon cancer, respectively. Based on the ROC curve, the ideal cutoff value of preoperative prediction scores to predict lymph node metastasis was established to be 287. Conclusion: The preoperative prediction scores is a useful indicator that can be applied to predict lymph node metastasis in gastric and colon cancer patients.


2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Aydin Eresen ◽  
Yu Li ◽  
Jia Yang ◽  
Junjie Shangguan ◽  
Yury Velichko ◽  
...  

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 51-51
Author(s):  
Toru Aoyama ◽  
Takaki Yoshikawa ◽  
Junya Shirai ◽  
Hirohito Fujikawa ◽  
Tsutomu Hayashi ◽  
...  

51 Background: Peritoneum is still the most frequent site of the recurrence in stage II/III gastric cancer patients although the survival was improved by S-1 adjuvant chemotherapy. The objective of this retrospective study was to clarify the risk factors of peritoneal recurrence in patients who received S-1 adjuvant chemotherapy. Methods: Peritoneal recurrence free survival (P-RFS) was examined in 100 gastric cancer patients who underwent curative D2 surgery, were diagnosed with stage II or III pathologically, and received adjuvant S-1 between June of 2002 and March of 2011. Uni- and multi- variate analyses were performed to identify risk factors by Cox’s proportional hazard analyses. Results: P-RFS was 64.3% at 3 years and 58.8% at 5 years. A total of 18 patients were diagnosed with peritoneal recurrence. Macroscopic tumor diameter, depth of tumor invasion, and lymph node metastasis were the significant factors by univariate analysis, while tumor diameter and lymph node metastasis were the only significant independent risk factors by multivariate analysis. Conclusions: The macroscopic tumor diameter and lymph node metastasis were the most important risk factors for P-RFS. When patients had these risk factors, S-1 was not sufficient to inhibit peritoneal recurrence. When developing a novel adjuvant chemotherapy targeting peritoneal metastasis in the future, clinical trials should be limited to these patients.


Sign in / Sign up

Export Citation Format

Share Document